

**Agreement with pharmaceutical companies and in clinical application at the first hospital:
Norwegian e-health technology will give better patient care globally**



- ***Gives the patient a better quality of life and frees up capacities in the health care system.***

Calpro has developed the e-health technology, CalproSmart™, which enables monitoring the illness situation at home and reporting to the physician via a mobile telephone app. Now, North Zealand Hospital, as the first hospital in the Norden countries, has made use of this, and the pharmaceutical companies, Janssen Pharmaceutica NV and MSD, will bring the technology to the health care industry.

- "Digitalization in the health care sector to create efficiencies and improve patient solutions is a priority area for government authorities and for the pharmaceutical industry. We are a small company and are very proud of having developed innovative technology which can provide to patients worldwide a better quality of life and at the same time free up resources in the health care system", maintains Anne Thjømmøe, CEO at Calpro.

Started up with medical discovery in the 1980's

Calpro was established in 1993 by three Norwegian researchers, who, in the 1980's, discovered the protein Calprotectin. This protein, which is a general marker for inflammation, is excreted in the stools when patients with IBD (Inflammatory Bowel Disease) develop inflammation in the intestine. IBD is the blanket term for chronic inflammatory diseases in the intestines, and the two most common ones are Ulcerative Colitis and Crohn's Disease.

The founders developed technology for measuring of the protein level that records the degree of inflammation, and thus how ill the patient is. These tests are used in large areas of the world to monitor the illness and to provide accurate treatment.

Enormous benefits for both patient and the health care system

Now, these patients can avoid having to travel to the hospital or send in stool samples which can take weeks for the results to come back. With the home test CalproSmart, the patient, on a proactive basis, can measure the level of protein and find out the result, which is then automatically and immediately sent to the physician via an application on his mobile phone.

- "The technology is a win-win situation for both the patient and for the health care sector. It frees up capacity because many consultations can be done by telephone or by e-mail. The patient receives a more timely and more suitable medical follow-up, something that reduces the need for emergency treatment, admission, and unnecessary colonoscopies. The test can show a relapse before the patient him/herself notices any symptoms, and the physician can set in motion medication in accordance with the test results", says Anne Thjømøe.

The first hospital off the mark

Professor Pia Munkholm has worked collaboratively with Calpro for many years and has done many studies on the company's products. She has now been given approval for the use of CalproSmart in her e-health clinic at North Zealand Hospital in Denmark, which is the first hospital in the Norden countries that has put the technology into use in clinical practice.

- "We are very pleased to be able to offer our patients the possibility of control over their own illness. To many of them, the illness is almost disabling, but with the app, one can monitor the symptoms and obtain advice on a timely basis", says Pia Munkholm.

The approximately 2,000 patients will thus monitor their calprotectin values from home, as opposed to going to the hospital.

- "The feedback from those who have used the app are without exception positive. Today, both patients and the health care system use considerable resources treating illness flare-ups on an outpatient basis, and on admissions that could have been avoided", states Munkholm.

Also, pharmaceutical companies see an enormous potential in support of patients and healthcare professionals

About two years ago, Calpro entered into an important agreement with the pharmaceutical firm MSD for distribution in Europe. CalproSmart is now being tested in hospitals in countries such as the Netherlands, Belgium, Czechoslovakia, Israel, and Italy, with the goal of implementation in clinical practice.

Now, Calpro has also entered into an agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson.

- "Just in Europe alone, it is estimated that as many as 2.5 – 3 million people have IDB. The technology has a very large catchment area as the authorities progressively see the advantages in using smart e-health technology", say Thjømøe.

This is how CalproSmart functions:

The patient is trained by a gastroenterologist registered nurse and is given a test kit for the home. A stool collector is mounted on the toilet, and a test sampler stick collects a bit of stool into a reagent bottle with a special liquid. The extract is dripped on to a test cassette. After 15 minutes, two coloured lines appear, which are photographed via the CalproSmart app on the mobile. The CalproSmart app gives immediate results on the mobile phone display where green, yellow, and red indicate respectively mild, moderate, and severe degrees of inflammation. In addition, the calprotectin value is shown in milligrams per kilo. The result is sent directly to the treating physician. See the instruction video by visiting:



Press Release September 2018

<https://www.youtube.com/watch?v=xn16BkDDUcY>

For further information contact:

Anne Thjømmøe, Admin. Director

Cell phone: 977 33 751

Email: athjomoe@calpro.no

About Calpro

Calpro was established in 1993 by the developers behind the ELISA technology which measures the level of calprotectin in stool samples. The company is the market leader in the USA and has a strong position in Europe. For more information, see www.calpro.no.